Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

@article{Damico2006PegaptanibSF,
  title={Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.},
  author={Donald J. D'amico and Harvey N Masonson and Manju Patel and Anthony P. Adamis and Emmett T. Cunningham and David R. Guyer and Barrett Katz},
  journal={Ophthalmology},
  year={2006},
  volume={113 6},
  pages={992-1001.e6}
}
OBJECTIVE To evaluate the safety of pegaptanib sodium injection, a specific vascular endothelial growth factor (VEGF) antagonist, in the treatment of neovascular age-related macular degeneration (AMD) during 2 years of therapy. DESIGN Two concurrent, prospective, randomized, multicenter, double-masked, sham-controlled studies. METHODS Patients with all angiographic choroidal neovascularization lesion compositions of AMD received either intravitreous pegaptanib sodium (0.3 mg, 1 mg, 3 mg) or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

Intravitreal injections: a review of the evidence for best practice: comment.

Clinical & experimental ophthalmology • 2014
View 3 Excerpts
Highly Influenced

Pharmacologic Therapy of Ocular Disease

Handbook of Experimental Pharmacology • 2017

Similar Papers

Loading similar papers…